the DBL report

Issue #110, September 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on July 23, 2019. The Committee reviewed Manufacturer submissions for seventeen (17) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of fifteen (15) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, sixteen (16) Drug Products underwent Expedited Review for listing on the *ADBL* effective August 1, 2019, and six (6) Drug Products underwent Expedited Review for listing on the *ADBL* effective September 1, 2019.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective August 1, 2019:

- **FASENRA* 30 mg/mL injection syringe** (benralizumab) (AZC) via Special Authorization (SA)
- **FYCOMPA* 2 mg, 4 mg, 6 mg, 8 mg, 10 mg & 12 mg tablets** (perampanel) (EIS) for the indication of primary generalized tonic-clonic (PGTC) seizures via SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (09/2019)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* effective September 1, 2019:

- **OZEMPIC* 1.34 mg/mL (0.25 mg or 0.5 mg dose) & 1.34 mg/mL (1 mg dose) pen injections** (semaglutide) (NNA) via Step Therapy/SA
- **VPRIV* 400 unit/vial injection** (velaglucerase alfa) (SHG) via SA

The following Drug Product was reviewed by CDR and added to the *ADBL* effective September 1, 2019:

- **ELELYSO* 200 unit/vial injection** (taliglucerase alfa) (PFI) via SA

Highlights of Drug Products Added

The following Drug Product was reviewed by the Expert Committee and added to the *ADBL* effective August 1, 2019:

- **XELJANZ XR* 11 mg extended-release tablet** (tofacitinib citrate) (PFI) via SA

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective September 1, 2019:

- **KEVZARA* 150 mg/1.14 mL & 200 mg/1.14 mL injection pens** (sarilumab) (SAV) via SA

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective August 1, 2019:

- **APO-DEFERASIROX (TYPE J)* 90 mg, 180 mg & 360 mg tablets** (deferasirox) (APX) via Step Therapy/SA

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of a New IC Grouping, effective September 1, 2019:

- **MAR-TROSPIUM* 20 mg tablet** (trospium chloride) (MAR) via Step Therapy/SA

Restricted Benefit Criteria Changes

The Restricted Benefit criteria for coverage for the following Drug Product have been revised effective September 1, 2019 to include the indication for intermittent treatment and additional treatment courses:

- **FIBRISTAL* 5 mg tablet** (ulipristal acetate) (ASC)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Product have been revised effective August 1, 2019:

- **NUCALA* 100 mg/mL vial injection** (mepolizumab) (GSK)

The Special Authorization criteria for coverage for the following Drug Products have been revised effective September 1, 2019:

- **GILENYA* 0.5 mg capsule** (fingolimod) (NOV)
- Lacosamide **50 mg, 100 mg, 150 mg & 200 mg tablets** (AUR, PMS, SDZ, TEV & UCB)
- Febuxostat* **80 mg tablet** (MAR & TAK)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*
ABC 81171 (09/2019)